|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS |
|
|
|
 |
|
|
Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy
|
|
Siamak (Sia) Daneshmand, MD
|
| Sia Daneshmand discusses a study published in European Urology which aimed to look at all the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information.
|
|
|
|
|
|
|
|
|
|
 |
|
|
Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy
|
|
Stephen B. Williams, MD
|
| Stephen Williams and Ashish Kamat discuss costs and survival analysis between radical cystectomy and trimodal therapy. He shares results of two studies which patients from 2002-2011 were looked at in both studies focusing on methodology/statistical analyses and the outline of outcomes.
|
|
|
|
|
|
|
|
|
|
 |
|
|
Improving Detection Rates of Bladder Cancer
|
Jens Bedke, MD
A multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, and treatment approaches for the variant histologies in bladder cancer.
|
|
|
|
|
|
|
|
|
 |
|
|
Optimal Surgical Approaches in Cystectomy
|
Piyush Agarwal, MD
Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RECENT DATA FROM CONFERENCES WORLDWIDE |
|
|
|
| Oncofid-P-B for the Treatment of BCG Unresponsive Carcinoma In Situ (CIS) of the Bladder – Results of the European Multicenter Phase 1 Study at the End of 12 Consecutive Weeks Intensive Course
|
| Rodolfo Hurle, MD
|
| The presented study was an open-label, multicenter, multinational, phase 1 study to evaluate the safety and efficacy of this drug in 20 patients with CIS +/- Ta/T1 who were unresponsive or intolerant to BCG and unwilling or unfit to undergo radical cystectomy.
|
|
|
|
|
|
| Changing the Paradigm in Intravesical Therapy for NMIBC
|
| Badrinath Konety, MD, MBA
|
| Dr. Badrinath Konety presented on intravesical therapy for non-muscle invasive bladder cancer (NMIBC), detailing current risk-based therapy, disease recurrence following BCG therapy, additional options for the intravesical treatment of NMIBC and some of the work being done involving immunotherapy in the setting of NMIBC
|
|
|
|
|
|
| Re-TURBT – Yes, No, or Maybe?
|
| Ashish Kamat, MD, MBBS
|
| Dr. Ashish Kamat presented on the important concept of restaging transurethral resection of the bladder tumor (TURBT). There has bee some discussion in the past regarding the need to perform another TURBT after the initial one, which is called the restaging TURBT (re-TURBT)
|
|
|
|
|
|
|
|
|
|
|
| Race and Guideline Based Treatment in Bladder Cancer
|
| Samuel Washington, MD
|
| Samuel Washington, MD from the University of California San Francisco, discussed race and guideline based treatment of bladder cancer. Access to care and socioeconomic status are known predictors for this disparity.
|
|
|
|
|
|
| Debate Bladder Cancer: The Optimal Management |
| The Optimal Management for a Healthy 65-year-old Male with High-Grade T1 Bladder Cancer is BCG Maintenance - Pro
|
| Paolo Gontero, MD
|
| Dr. Paolo Gontero was the first debater, suggesting therapy with BCG for this patient. There is no doubt that a T1 high-grade disease is considered an aggressive non-muscle invasive bladder cancer (NMIBC). The progression rate of this specific disease is between 27-65%. There is a treatment dilemma having to decide between early aggressive radical cystectomy or conservative therapy with BCG.
|
|
|
|
|
|
| The Optimal Management for a Healthy 65-year-old Male with High-Grade T1 Bladder Cancer is BCG Maintenance - CON
|
| Seth Lerner, MD
|
| Dr. Lerner debated against BCG therapy in this particular case. T1G3 with CIS has a worse prognosis than a T1G3 tumor without CIS.1 It is also important to consider that these patients can be upstaged at a re-TUR. If they are shown to be upstaged, their survival is even worse. According to Dr. Lerner the correct and optimal treatment, in this case, should be early radical cystectomy.
|
|
|
|
|
|
|
